RxDoctor Payments Data

Luis Fong

Psychiatric/Mental Health · Phoenix, AZNPI 1598259467

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $50,600 of the $59,079 with a category attached, or 85.6%. AbbVie accounts for 91.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $22,260 and has fallen 69.2% since, to $6,855 in 2025. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,079in general payments, 2019–2025

Across 368 payments — averaging $160.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$54K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Sunovion Pharmaceuticals Inc.$520
  • Otsuka America Pharmaceutical, Inc.$254
  • Johnson & Johnson$194
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$50,60086%
  • Travel & lodging$1,8133%
  • Food & beverage$6,57411%
  • Education$920%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,079 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl52$75,669
VyvanseLisdexamfetamine Dimesylate12$4,490
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$3,219
Vilazodone Hcl13$2,917
Buspirone Hcl93$1,704
Bupropion Hcl SrBupropion Hcl58$1,439
Quetiapine Fumarate43$992
Clonazepam82$966
Mirtazapine61$855
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$782
Aripiprazole34$750
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$654
Venlafaxine Hcl ErVenlafaxine Hcl34$614
Duloxetine Hcl22$589
Bupropion XlBupropion Hcl13$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$53,972$75,66952 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$136$4,49012 claims
Lilly USA, LLCOlanzapine$12$29314 claims
Almatica Pharma LLCSertraline Hcl$16$19524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →